T cell depletion of allogeneic stem cell grafts with anti-CD 52 monoclonal antibodies: the Ulm experience from 1983-1999.
Bunjes
D
D
Stem Cell Transplantation Programme, Department of Haematology/Oncology, Ulm University Hospital, Robert-Koch-Strasse 8, 89081, Ulm, Germany. donald.bunjes@medizin.uni-ulm.de
D000208:Acute Disease; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000276:immunology*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000276:immunology; D015703:Antigens, CD / Q000276:immunology*; D000951:Antigens, Neoplasm; D016026:Bone Marrow Transplantation; D000074301:CD52 Antigen; D002986:Clinical Trials as Topic; D006023:Glycoproteins / Q000276:immunology*; D006084:Graft Rejection; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D015994:Incidence; D007938:Leukemia / Q000628:therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D008212:Lymphocyte Depletion; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D012449:Safety; D016879:Salvage Therapy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D000074323:Alemtuzumab